IBS
Conditions
Interventions
Group A:Mild warm moxibustion ST36(bilateral),RN12,RN6
Group B:Mild warm moxibustion ST36(bilateral), RN12,RN6
Group C:Electroacupuncture ST36(bilateral),ST37(bilateral)
Group D:Electroacupuncture ST36(bilateral),ST37(bilateral)
Sponsors
Shanghai University of TCM Affiliated Longhua Hospital, Shanghai Institute of Acupuncture and Meridian
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: D-IBS: 1. Diagnosed as D-IBS according to Rome III criterion; 2. Aged 18-65, both male and female; 3. Willing to participate in the study and sign the informed consent. C-IBS: 1. Diagnosed as C-IBS according to Rome III criterion; 2. Aged 18-65, both male and female; 3. Willing to participate in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: D-IBS: 1. Patients with structural disease on the intestines; 2. Constipation-dominated IBS; 3. A-IBS patients; 4. Patients who take cisapride, and other medicinal herbs which may affect the effects; 5. Patients companied with some primary disease such as cerebral vessels diseases, liver or kidney disease and disorders of hematopoietic system etc which seriously affected life or Patients with serious mental disorder; 6. Patients younger than 18 years old and older than 65 years old; 7. Patients in a pregnancy or lactation. C-IBS: 1. Patients with structural disease on the intestines; 2. Diarrhea-dominated IBS; 3.A-IBS patients; 4.Patients who take cisapride, and other medicinal herbs which may affect the effects; 5. Patients companied with some primary disease such as cerebral vessels diseases, liver or kidney disease and disorders of hematopoietic system etc which seriously affected life or Patients with serious mental disorder; 6. Patients younger than 18 years old and older than 65 years old; 7. Patients in a pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Therapeutic effect;Functional MR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Colonic expressing of SP, VIP;Colonic histopathological changes;Colonic expressing of 5-HT, 5-HT3R, 5-HT4; | — |
Countries
China
Contacts
Public ContactYin Shi
Outcome results
None listed